This page shows the latest blood disorders news and features for those working in and with pharma, biotech and healthcare.
Manufactured blood cells could revolutionise treatments for people with blood disorders. ... It is hoped the approach could ‘revolutionise’ treatments for people with blood disorders such as sickle cell disease and rare blood types who require
company’s blood disorders portfolio. ... an investigational oral, once-daily, selective pyruvate kinase-R (PKR) activator, being developed to improve anaemia and red blood cell health in people with sickle cell disease (SCD).
Pfizer has announced the completion of its acquisition of Global Blood Therapeutics (GBT), a biopharma focusing on drug discovery and development of treatments for rare blood disorders including sickle cell disease ... SCD is a lifelong, incurable
The acquisition will focus on expanding the company’s blood disorders portfolio. ... Novo Nordisk and Forma Therapeutics (Forma) have entered into a definitive agreement, under which Novo Nordisk will acquire Forma in a deal worth $1.1bn to expand its
The acquisition will help accelerate research into sickle cell disease. Pfizer and Global Blood Therapeutics (GBT) have announced that Pfizer will acquire GBT. ... GBT focuses on drug discovery and development for rare blood disorders and Pfizer has an
Haemophilia A is an inherited, serious disease whereby a patient’s blood is unable to clot properly, which can often cause uncontrolled and spontaneous bleeding. ... disorders. More than 22, 000 people with haemophilia in over 112 countries have
More from news
Approximately 3 fully matching, plus 51 partially matching documents found.
In the meantime, Sanofi is stepping up its focus in other areas like immunological and inflammatory diseases, rare blood disorders and vaccines, as well as cancer – an area it had been
The company is now projecting long-term improvements across its two main areas of haemophilia and growth hormone disorders, with confidence radiating into all quarters of its business. ... disorders field because we have access to this great science and
This approach is now being applied to diseases such as sickle cell, a group of inherited blood disorders.
This approach is now being applied to diseases such as sickle cell, a group of inherited blood disorders.
well as a pipeline of candidates focused on rare blood disorders. ... Portfolio/pipeline in haemophilia and other rare blood disorders. Acquisition company. 11, 600.
More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.
Kiadis has a focus on research, development and commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders, including its lead product Atir. ... Atir achieved some extremely compelling clinical
blood disorders.
Will lead development of stem cell-based treatments for blood conditions and cancer. ... Dr Reed joins from Cerus Corporation and will lead the development of Cellerant's stem cell-based cellular and antibody therapies for blood disorders and cancer.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
The cancer landscape is changing. Immunotherapeutic advances are driving significant improvements in treatment options for sufferers of many types of cancers and blood disorders. ... Within blood cancers, PD-(L) 1s and also monoclonal antibodies, in
Previously Kirsty worked on MedEd accounts at Adventis Health. During her marketing degree she also spent a year at Baxter Healthcare as a marketing executive working on rare blood disorders.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...